EP0925071A4 - Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions - Google Patents

Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions

Info

Publication number
EP0925071A4
EP0925071A4 EP97940948A EP97940948A EP0925071A4 EP 0925071 A4 EP0925071 A4 EP 0925071A4 EP 97940948 A EP97940948 A EP 97940948A EP 97940948 A EP97940948 A EP 97940948A EP 0925071 A4 EP0925071 A4 EP 0925071A4
Authority
EP
European Patent Office
Prior art keywords
muc
inflammatory
treatment
therapeutic agent
autoimmune conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97940948A
Other languages
German (de)
French (fr)
Other versions
EP0925071A1 (en
Inventor
B Michael Longenecker
Judith C Hugh
Lyle H Regimbald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncothyreon Canada Inc
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Publication of EP0925071A1 publication Critical patent/EP0925071A1/en
Publication of EP0925071A4 publication Critical patent/EP0925071A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
EP97940948A 1996-09-10 1997-09-10 Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions Withdrawn EP0925071A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2571896P 1996-09-10 1996-09-10
US25718P 1996-09-10
PCT/US1997/015928 WO1998010783A1 (en) 1996-09-10 1997-09-10 Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions

Publications (2)

Publication Number Publication Date
EP0925071A1 EP0925071A1 (en) 1999-06-30
EP0925071A4 true EP0925071A4 (en) 2000-09-13

Family

ID=21827678

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97940948A Withdrawn EP0925071A4 (en) 1996-09-10 1997-09-10 Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions

Country Status (5)

Country Link
EP (1) EP0925071A4 (en)
JP (1) JP2001501599A (en)
AU (1) AU741258B2 (en)
CA (1) CA2264748A1 (en)
WO (1) WO1998010783A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2269349A1 (en) * 1996-10-25 1998-04-30 Dana-Farber Cancer Institute, Inc. Mucin-mediated immunomodulation
AU2354700A (en) * 1998-12-11 2000-06-26 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
DE10056136A1 (en) * 2000-11-07 2002-05-16 Nemod New Modalities Inhibiting leukocyte or tumor cell adhesion to vascular endothelial cells e.g. for combating inflammation or metastasis, using e.g. pregnancy proteins or selectin binding liposomes containing calcium-binding compound
WO2002062319A2 (en) * 2001-01-19 2002-08-15 Corixa Corporation Microsphere delivery of mucin peptides
SI1529060T1 (en) 2002-07-22 2015-01-30 Glycotope Gmbh Method for the production of an immunostimulating mucin (muc1)
WO2010087521A1 (en) 2009-01-29 2010-08-05 独立行政法人理化学研究所 Combined preparation for treating joint diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017300A1 (en) * 1996-10-25 1998-04-30 Dana-Farber Cancer Institute, Inc. Mucin-mediated immunomodulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017300A1 (en) * 1996-10-25 1998-04-30 Dana-Farber Cancer Institute, Inc. Mucin-mediated immunomodulation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGRAWAL B ET AL: "In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors", JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 157, no. 5, 1 September 1996 (1996-09-01), pages 2089 - 2095, XP002078857, ISSN: 0022-1767 *
REDDISH MARK A ET AL: "Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy.", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 42, no. 5, 1996, pages 303 - 309, XP000914873, ISSN: 0340-7004 *
See also references of WO9810783A1 *
VAN DE WIEL-VAN KEMENADE ELLY ET AL: "Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.", JOURNAL OF IMMUNOLOGY, vol. 151, no. 2, 1993, pages 767 - 776, XP002141253, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
AU741258B2 (en) 2001-11-29
JP2001501599A (en) 2001-02-06
WO1998010783A1 (en) 1998-03-19
AU4261397A (en) 1998-04-02
EP0925071A1 (en) 1999-06-30
CA2264748A1 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
GB9617021D0 (en) Novel peptides for treatment of inflammation and shock
GB0015235D0 (en) Compositions for the treatment of skin and anorectal conditions
IL126758A0 (en) Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
IL132758A0 (en) Methods for treating inflammation and inflammatory diseases using padprt
EP0960191A4 (en) Compositions and methods for use of defensin
HUP9902889A3 (en) The use of 3-phenyl-4-(4-methylsulphonyl)-phenyl-2-(5h)-furanone for producing anti inflammatory medicaments and such medicaments
HUP0102907A1 (en) Diagnostics for and mediators of inflammatory disorders
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
GB2331398B (en) Bearings and supports
HK1018271A1 (en) Substituted benzylamines and their use for the treatment of depression
AU1556497A (en) Agents for the treatment and prevention of aids
GB9726342D0 (en) Fixing screw for fixing atlas and axis
EP0925071A4 (en) Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
IL120606A0 (en) Apparatus and method for the reduction of snoring
HK1022267A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis
GB2265669B (en) Arrangement of compressor and mount for the compressor
ZA9710989B (en) Polyprolyl inhibitors of cyclophilin
GB9621825D0 (en) Microparticles and their use as therapeutic vehicles
ZA972728B (en) Apparatus and procedure for minimizing the risks of inhalative no-therapy.
GB9609944D0 (en) An improvement in the treatment of wastes
AU8049098A (en) Composition and methods for the treatment of inflammatory diseases
AU4962797A (en) Radiofrequency device for the treatment of cellulitis and other therapies
GB9617346D0 (en) Therapeutic methods and compositions for use therein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990401

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/16 A, 7A 61K 38/17 B, 7A 61P 37/06 B, 7C 07K 14/47 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000727

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030621